TABLE 5.

Characteristics of studies included in meta-analysis (Wu et al., 2022).

Study	Treatment	Cancer	PPI type
Chalabi 2020	Atezolizumab	NSCLC	Omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, and dexlansoprazole
Hopkins 2020	Atezolizumab	Urothelial cancer	Omeprazole, pantoprazole, esomeprazole, lansoprazole, rabeprazole, and dexlansoprazole
Hopkins 2021	Atezolizumab	NSCLC	Omeprazole, pantoprazole, esomeprazole, lansoprazole, rabeprazole, and dexlansoprazole
Svaton 2020	Nivolumab	NSCLC	Omeprazole, pantoprazole, and lansoprazole

PPI, proton pump inhibitor; NSCLC, non-small-cell lung cancer.